Journal
LIFE-BASEL
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/life11020119
Keywords
sarcopenia; non-alcoholic fatty liver disease; obesity; insulin resistance; prevalence; metabolic diseases
Categories
Ask authors/readers for more resources
The prevalence of non-alcoholic fatty liver disease (NAFLD) is continuously increasing, closely associated with metabolic disorders such as obesity and insulin resistance. Sarcopenia and sarcopenic obesity have a negative impact on outcomes for individuals with NAFLD, and are expected to rise as obesity rates increase. Further research is needed to better define and manage these conditions.
Non-alcoholic fatty liver disease (NAFLD) continues to rise and has become the most common cause of chronic liver disease among all ages and ethnicities. Metabolic disorders, such as obesity and insulin resistance, are closely associated with sarcopenia and NAFLD. Sarcopenic obesity is a clinical disorder characterized by the simultaneous loss of skeletal muscle and gain of adipose tissue. It is associated with worse outcomes in individuals with NAFLD. It is projected that NAFLD and sarcopenia will rise as the prevalence of obesity continues to increase at an unparallel rate. Recently, sarcopenia and sarcopenic obesity have gained considerable interest, but we still lack a well-defined definition and a management approach. Therefore, it is imperative to continue shining the light on this topic and better understand the underlying mechanism as well as treatment options. In this review article, we aimed to address the pathophysiology, impact, and outcomes of sarcopenic obesity on NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available